News & Updates
Pro-Tects – A Novel Solution to the Challenge of Biologic Instability
Shane Smith, Eoin Scanlan and Paula Colavita discuss the difficulty inherent in developing parenteral biologic products due to the challenge of creating a stable formulation in the face of surface-mediated protein aggregation and introduce Pro-Tects – Glycome BioPharma’s patented surface-treatment technology platform that offers a solution to this critical issue without introducing further development challenges.
Surface-Mediated Aggregation - Control of the Liquid-Solid Interfacial Stress
Shane Smith, Eoin Scanlan and Paula Colavita discuss how the company’s technology has evolved to create a stable and biocompatible coating that maintains device performance and safety.
Aggregation of Protein Therapeutics Enhances their Immunogenicity: Causes and Mitigation Strategies
Protein aggregation in biotherapeutics has been identified to increase immunogenicity, leading to immune-mediated adverse effects, such as severe allergic responses including anaphylaxis. The induction of anti-drug antibodies (ADAs) moreover enhances drug clearance rates, and can directly block therapeutic function. In this review, identified immune activation mechanisms triggered by protein aggregates are discussed, as well as physicochemical properties of aggregates, such as size and shape, which contribute to immunogenicity.